Literature DB >> 2413861

In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).

D W Fry, T J Boritzki, J A Besserer, R C Jackson.   

Abstract

CI-937 and CI-942 belong to a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles), and are being further developed as antitumor drugs based on their curative properties against murine solid tumour models. The biochemical effects of these agents were studied in L1210 leukemia in relation to other clinically used intercalators. After a 1-hr exposure, CI-937 and CI-942 reduced the cloning efficiency of L1210 cells by 50% at 3.0 X 10(-8) and 1.5 X 10(-7) M respectively. Based on an ethidium displacement assay, these drugs bound strongly to DNA, reducing the fluorescence of an ethidium-DNA complex by 50% at concentrations of 23 and 33 nM for CI-937 and CI-942 respectively. This was comparable to mitoxantrone at 15 nM, but much more potent than Amsacrine which required over 1.3 microM. A distinct property of the anthrapyrazoles was a much more potent inhibitory effect on whole cell DNA synthesis than on RNA synthesis. After L1210 cells were exposed to drug for 2 hr the concentration needed to inhibit DNA synthesis by 50% was 0.33 and 0.57 microM for CI-937 and CI-942, respectively, whereas 2.0 and 11.3 microM were required to inhibit RNA synthesis by the same extent. This was in contrast to Adriamycin and mitoxantrone which inhibited both activities equally at similar concentrations. It was apparent that the inhibition of these processes was not due to substrate depletion since intracellular ribonucleoside and deoxyribonucleoside triphosphates either remained constant or were elevated after a 2-hr exposure to 1 or 10 microM drug. A similar discriminatory effect was observed on DNA and RNA polymerase in permeabilized cells, and the inhibition of nucleic acid synthesis in this system could be reversed by exogenously added DNA. Since the high incidence of cardiotoxicity associated with the administration of anthracyclines has been related to the formation of reactive oxygen species, the ability of the anthrapyrazoles to augment superoxide dismutase sensitive oxygen consumption was observed in a rat liver microsomal system. CI-937 and CI-942 induced 5- and 10-fold less oxygen consumption than Adriamycin, producing rates of 12.4, 24.2 and 138.9 nmoles/min/mg microsomal protein, respectively, at a drug concentration of 0.5 mM.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413861     DOI: 10.1016/0006-2952(85)90724-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Authors:  S K Williamson; J J Crowley; R Livingston; A Hantel; J H Doroshow
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

2.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology.

Authors:  S G Allan; J Cummings; S Evans; M Nicolson; M E Stewart; J Cassidy; M Soukop; S B Kaye; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.

Authors:  M M Zalupski; J Benedetti; S P Balcerzak; L F Hutchins; R J Belt; A Hantel; J W Goodwin
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

5.  Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.

Authors:  S L Berg; F M Balis; K S Godwin; D G Poplack
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

6.  Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).

Authors:  S K Frank; D A Mathiesen; M Szurszewski; M J Kuffel; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells.

Authors:  C A Carter; K W Bair
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

8.  Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.

Authors:  A Allen; M Wolf; E D Crawford; M P Davis; R B Natale; M L Barnett
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

9.  A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

Authors:  J A Sosman; L E Flaherty; P Y Liu; W Fletcher; J A Thompson; A Hantel; V Sondak
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

10.  The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Authors:  Brian B Hasinoff; Hong Liang; Xing Wu; Lynn J Guziec; Frank S Guziec; Kyle Marshall; Jack C Yalowich
Journal:  Bioorg Med Chem       Date:  2008-01-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.